No definition available.
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
519972 |
1. Apply sex-specific ruleNone |
519972 |
2. Check conditionsNone |
519972 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters: 2 out of 7 registries used, show all original rules. |
101 |
4. Check minimum number of eventsNone |
101 |
5. Include endpoints |
120 |
6. Filter based on genotype QC (FinnGen only) |
114 |
Control definitions (FinnGen only)
- Control exclude
- E4_OBESITY_HYPER
Extra metadata
- Level in the ICD hierarchy
- 3
- First used in FinnGen datafreeze
- DF2
Similar endpoints
↥List of similar endpoints to
Other hyperalimentation
based on the number of shared cases.
Similar with more cases:
- Obesity and other hyperalimentation
- Endocrine, nutritional and metabolic diseases
- Any event in hilmo or specialist outpatient
Similar with less cases:
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 767 | 460 | 298 |
| Only index persons | 615 | 384 | 231 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.01 | 0.01 | 0.01 |
| Only index persons | 0.01 | 0.01 | 0.01 |
| Median age at first event (years) | |||
| Whole population | 49.68 | 48.81 | 50.63 |
| Only index persons | 48.07 | 47.96 | 48.24 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 114 | 76 | 38 |
| Unadjusted period prevalence (%) | 0.02 | 0.03 | 0.02 |
| Median age at first event (years) | 51.73 | 48.67 | 57.84 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 120
- Matched controls
- 1200
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
E68
ICD-10 Finland
Sequelae of hyperalimentation
+∞
73.7
63
*
E66.01
ICD-10 Finland
Obesity due to excess calories
26.3
48.5
37
20
E66.8
ICD-10 Finland
Other obesity
254.0
37.0
36
*
E66.00
ICD-10 Finland
Metabolic syndrome
23.9
19.8
28
15
E66.9
ICD-10 Finland
Obesity, unspecified
69.9
16.3
18
*
QBJ30
NOMESCO Finland
Correction of abdominal apron
+∞
16.0
15
*
E67.3
ICD-10 Finland
Hypervitaminosis D
+∞
14.9
14
*
JDF11
NOMESCO Finland
Laparoscopic gastric bypass
+∞
13.8
13
*
T82
ICPC
Obesity
19.0
12.1
18
11
103
Kela drug reimbursment
Diabetes, insulin-treated
3.9
11.4
47
169
E66.2
ICD-10 Finland
Extreme obesity with alveolar hypoventilation
+∞
10.6
10
*
E67.8
ICD-10 Finland
Other specified hyperalimentation
+∞
10.6
10
*
SPAT1262
SPAT
Handing over of treatment supplies
4.3
10.2
31
89
215
Kela drug reimbursment
Diabetes, non-insulin-treated
3.7
9.5
40
144
E67.2
ICD-10 Finland
Megavitamin-B6syndrome
+∞
9.5
9
*
27799
ICD-8 Finland
Obesity not specified as of endocrine origin
+∞
9.5
9
*
27899
ICD-8 Finland
Other hyperalimentation, Other and unspecified
+∞
9.5
9
*
N02AX02
ATC
tramadol; systemic, rectal
3.2
9.2
69
353
A10BA02
ATC
metformin; oral
3.4
9.0
46
187
Z71.3
ICD-10 Finland
Dietary counselling and surveillance
13.0
8.9
15
13
UJD10
NOMESCO Finland
Esophagoscopy, gastroscopy and duodenoscopy
3.2
8.8
51
223
310
Kela drug reimbursment
Orlistat, sibutramine and other major and expensive medicines used to treat obesity
96.6
8.5
9
*
E11.9
ICD-10 Finland
Type 2 diabetes mellitus, without complications
3.3
7.9
40
160
ZXD05
NOMESCO Finland
Urgent procedure
2.9
7.3
50
237
SPAT1215
SPAT
Assessment of need for medical rehabilitation
9.2
7.1
14
17
JKA21
NOMESCO Finland
Laparoscopic cholecystectomy
3.7
7.0
25
79
J01FF01
ATC
clindamycin; systemic
2.9
7.0
44
198
C03CA01
ATC
furosemide; systemic
2.8
7.0
49
234
SPAT1306
SPAT
Counselling and guidance related to nutrition and weight management
3.6
6.7
25
82
N06AB03
ATC
fluoxetine; oral
3.6
6.5
24
78
SPAT1229
SPAT
Assessment of need for aid
4.4
6.4
17
43
E66
ICD-10 Finland
Obesity
9.4
6.2
12
14
T90
ICPC
Diabetes non-insulin dependent
2.9
6.1
35
148
G47.3
ICD-10 Finland
Sleep apnoea
2.9
6.1
35
148
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
77
371
4.00
12.33
3.8
2.2
76.85
80.36
nmol/l
0.41
68
328
76
384
3.67
10.88
5.2
4.3
35.44
35.80
g/l
0.18
69
363
53
213
3.67
10.86
2.6
1.8
3.02
3.10
mg/l
0.08
44
186
71
357
3.42
9.98
2.7
1.8
111.49
95.88
pmol/l
1.32
44
172
53
247
3.05
8.08
4.6
3.4
6.43
6.13
mg/mmol
0.04
30
151
43
181
3.14
7.79
2.1
1.7
1128.48
1297.24
nmol/l
0.48
33
134
42
198
2.72
5.99
2.0
1.7
499.15
471.18
pmol/l
0.13
33
164
73
450
2.59
5.98
10.4
6.2
1.21
1.22
mmol/l
0.39
62
371
45
223
2.63
5.78
1.9
1.5
20.92
21.73
nmol/l
0.12
36
187
67
407
2.46
5.53
10.4
5.5
1.20
1.22
mmol/l
1.47
62
367
56
319
2.42
5.26
2.7
3.3
2.31
2.36
mmol/l
1.75
48
286
68
440
2.26
4.56
3.0
2.5
—
—
—
0
0
41
223
2.27
4.11
1.7
1.7
0.88
1.09
mg/l
0.36
31
175
62
402
2.12
3.97
4.0
2.6
129.13
100.17
ug/l
0.43
54
364
18
67
2.98
3.86
1.6
1.6
—
—
—
0
0
64
434
2.02
3.50
9.3
11.9
1.10
1.18
inr
0.53
21
136
9
18
5.31
3.44
1.2
1.1
—
—
—
0
0
28
140
2.30
3.35
2.4
1.8
29.32
29.53
s
0.09
28
134
44
265
2.04
3.31
4.3
2.7
0.13
0.46
e6/l
1.95
35
203
52
336
1.97
3.19
4.1
2.9
—
—
—
0
0
11
30
3.93
3.18
1.4
1.4
179.67
316.72
ug/g
—
6
17
96
776
2.19
2.99
10.1
7.7
82.96
76.72
u/l
0.81
96
728
37
218
2.01
2.91
2.8
2.3
—
—
—
0
0
42
262
1.93
2.79
3.0
3.1
1086.90
1413.40
ng/l
0.31
31
220
25
129
2.18
2.76
3.7
2.6
4.80
3.09
e6/l
0.23
13
71
92
741
2.04
2.76
5.0
4.0
14.73
14.79
pmol/l
0.06
80
671
11
36
3.26
2.64
1.0
1.4
—
—
—
0
0
22
110
2.22
2.61
5.3
4.4
34.40
33.31
%
0.19
15
74
39
243
1.90
2.58
2.8
3.0
345.17
4342.11
umol/l
1.06
30
212
5
7
7.39
2.57
1.2
1.0
—
—
—
0
0
103
882
2.18
2.36
8.3
5.1
41.73
39.39
mmol/mol
1.41
93
830
37
237
1.81
2.21
1.3
1.2
0.59
0.75
u/ml
—
10
59
7
19
3.84
2.18
2.9
2.5
26.97
24.62
mmol/l
—
7
19
15
70
2.31
2.08
3.9
3.7
65.60
79.01
ng/l
—
10
60
12
51
2.50
2.02
1.5
1.5
—
—
—
0
0
103
901
2.01
1.93
22.0
13.1
78.69
81.79
ml/min/173m2
0.59
90
746
7
22
3.31
1.91
1.6
1.3
—
—
—
0
0
51
375
1.63
1.80
5.2
4.0
74.69
29.94
ng/l
0.72
39
254
19
104
1.98
1.80
9.2
6.9
103.32
104.45
mmol/l
0.42
19
104
6
18
3.45
1.77
1.0
1.9
—
—
—
0
0
7
24
3.03
1.75
2.6
2.3
133.14
126.87
g/l
—
7
16
5
13
3.96
1.73
1.4
1.2
—
—
—
0
0
9
38
2.48
1.49
1.7
1.2
—
—
—
0
0
9
38
2.48
1.49
1.7
1.2
—
—
—
0
0
6
22
2.81
1.45
1.2
1.5
—
46.30
—
0
5
108
987
1.94
1.37
26.9
15.4
3.99
3.96
mmol/l
0.51
103
951
23
147
1.70
1.36
3.9
2.4
0.81
1.09
e6/l
0.31
11
87
11
55
2.10
1.32
1.3
1.2
—
—
—
0
0
69
573
1.48
1.28
9.2
10.1
4.71
4.02
e9/l
1.60
62
504
6
25
2.47
1.26
1.2
1.4
—
1.95
—
0
6
16
95
1.79
1.21
3.7
3.7
—
—
—
0
0
5
20
2.56
1.16
3.4
2.7
17.08
16.22
%
—
5
8
5
22
2.33
1.04
1.8
1.7
—
—
—
0
0
98
892
1.54
1.01
6.6
4.6
1.90
1.89
mu/l
0.03
89
808
11
62
1.85
0.98
1.6
1.3
—
—
—
0
0
57
474
1.39
0.97
5.7
5.1
0.00
0.00
estimate
-0.00
14
107
84
746
1.42
0.96
5.6
3.9
18.57
10.61
mm/h
3.21
77
681
57
476
1.38
0.93
3.7
3.9
0.00
0.00
estimate
-0.00
16
110
24
172
1.49
0.90
1.6
1.3
18.14
28.68
iu/ml
—
7
65
57
481
1.35
0.86
3.9
3.9
0.00
0.00
estimate
-0.00
16
101
8
46
1.79
0.84
6.5
5.6
24.15
25.52
mmol/l
—
8
46
105
981
1.56
0.83
24.6
13.7
27.40
21.69
mg/l
1.03
98
748
8
47
1.75
0.82
3.5
3.4
53.34
44.54
%
—
8
47
13
82
1.66
0.82
13.5
4.1
1.20
1.23
mmol/l
1.10
13
70
26
194
1.43
0.80
1.6
1.6
—
—
—
0
0
7
38
1.89
0.75
2.0
2.2
—
—
—
0
0
98
909
1.43
0.74
5.1
3.8
1.50
1.24
mmol/l
1.25
86
838
5
27
1.89
0.69
1.2
2.1
—
—
—
0
0
100
936
1.41
0.67
5.8
4.3
6.34
5.84
mmol/l
2.18
88
857
22
167
1.39
0.62
1.4
1.3
1.19
9.73
u/ml
—
7
67
100
940
1.38
0.61
5.8
4.2
1.41
1.51
mmol/l
1.52
90
871
8
52
1.58
0.61
10.1
8.6
0.51
0.79
%
—
8
52
6
35
1.75
0.58
1.7
2.0
—
—
—
0
0
20
152
1.38
0.57
1.8
1.9
—
—
—
0
0
6
39
1.57
0.54
1.3
1.9
—
—
—
0
0
100
946
1.34
0.53
5.7
4.2
4.52
4.68
mmol/l
0.91
90
881
7
45
1.59
0.50
1.3
1.8
—
—
—
0
0
14
103
1.41
0.48
1.8
1.8
—
—
—
0
0
7
48
1.49
0.48
3.4
2.8
26.69
25.05
mmol/l
—
7
48
30
250
1.27
0.46
2.0
1.5
1.84
1.32
mmol/l
1.10
23
212
0
16
0.00
0.41
0.0
1.2
—
0.50
—
0
9
5
35
1.45
0.40
2.6
1.7
—
—
—
0
0
6
41
1.49
0.36
1.3
1.3
25.03
22.85
iu/l
—
6
35
6
41
1.49
0.36
4.0
3.3
11.00
230.39
u/ml
—
6
35
7
52
1.37
0.32
9.7
8.7
0.87
1.51
%
—
7
52
14
114
1.26
0.26
6.1
9.2
—
—
—
0
0
41
373
1.15
0.26
3.9
4.1
—
—
—
0
0
14
116
1.23
0.23
1.9
1.9
—
—
—
0
0
0
11
0.00
0.21
0.0
2.5
—
—
—
0
0
0
10
0.00
0.21
0.0
1.4
—
—
—
0
0
0
10
0.00
0.21
0.0
1.6
—
—
—
0
0
0
13
0.00
0.21
0.0
4.8
—
139.23
—
0
13
20
176
1.16
0.19
3.7
3.2
718.51
120.45
ng/l
0.39
15
126
88
851
1.13
0.19
24.7
16.2
16.09
14.81
%
0.92
88
838
62
651
0.90
0.18
3.4
3.1
—
—
—
0
0
99
966
1.14
0.17
6.2
4.6
2.55
2.76
mmol/l
1.77
88
890
17
192
0.87
0.16
3.2
4.4
18.73
22.79
%
—
7
86
14
160
0.86
0.15
1.0
1.4
—
—
—
0
0
12
107
1.13
0.09
1.5
1.6
—
—
—
0
0
26
270
0.95
0.03
3.7
4.3
0.00
0.00
estimate
-0.00
15
104
10
94
1.07
0.01
2.7
1.7
—
—
—
0
0
15
145
1.04
0.00
2.9
2.9
0.69
0.70
ug/l
—
10
94
0
9
0.00
0.00
0.0
1.0
—
—
—
0
0
0
9
0.00
0.00
0.0
1.1
—
—
—
0
0
11
110
1.00
-0.00
1.5
1.7
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.8
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.6
—
17.98
—
0
5
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.7
—
7.89
—
0
8
0
6
0.00
-0.00
0.0
1.5
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.8
—
—
—
0
0
0
5
0.00
-0.00
0.0
5.6
—
—
—
0
0
0
8
0.00
-0.00
0.0
3.0
—
16.34
—
0
8
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.8
—
—
—
0
0
5
54
0.92
-0.00
1.0
1.1
—
—
—
0
0
5
51
0.98
-0.00
1.8
1.5
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.8
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.6
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.7
—
—
—
0
0
Mortality – FinRegistry
↥Association
Association between endpoint E4_HYPERALI and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| E4_HYPERALI | 2.001 [1.3, 3.08] | 0.002 |
| Birth year | 0.997 [0.99, 1.01] | 0.458 |
During the follow-up period (1.1.1998 — 31.12.2019), 64 out of 272 females with E4_HYPERALI died.
Males
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| E4_HYPERALI | 3.536 [2.12, 5.89] | < 0.001 |
| Birth year | 0.988 [0.98, 1.0] | 0.011 |
During the follow-up period (1.1.1998 — 31.12.2019), 65 out of 172 males with E4_HYPERALI died.
Mortality risk
Mortality risk for people of age
years, who have E4_HYPERALI.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.189% | 0.859% |
| 5 | 1.144% | 4.315% |
| 10 | 3.079% | 10.302% |
| 15 | 5.724% | 18.891% |
| 20 | 9.954% | 29.966% |
Relationships between endpoints
↥Index endpoint: E4_HYPERALI – Other hyperalimentation
GWS hits: -
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data